Richard Ingraham
About Richard Ingraham
Richard Ingraham is a Scientific Review Officer with extensive expertise in the biophysical characterization of proteins and their interactions, contributing to drug discovery at both pre-clinical and clinical levels. He has held various academic and industry positions, including roles at Boehringer Ingelheim Pharmaceuticals and the National Institutes of Health.
Work at National Institutes of Health
Richard Ingraham has served as a Scientific Review Officer at the National Institutes of Health since 2010. In this role, he is responsible for organizing and running a grant review study section that focuses on 'Skeletal Muscle and Exercise Physiology.' This section covers various aspects of skeletal muscle biology, development, and contractile biophysics. His position involves evaluating research proposals and contributing to the advancement of scientific knowledge in the field.
Education and Expertise
Richard Ingraham holds a Ph.D. in Biochemistry from the University of Iowa, where he studied from 1978 to 1984. He also earned an M.S. in Biochemistry from the same institution, completing his studies from 1978 to 1981. Prior to this, he obtained a B.S. in Chemistry from Louisiana State University, studying from 1974 to 1978. His educational background provides a strong foundation for his expertise in biophysical characterization of proteins and their interactions, which is crucial for drug discovery.
Background
Richard Ingraham began his academic journey at Ames Senior High, where he studied from 1971 to 1974. He then pursued higher education, culminating in advanced degrees in Biochemistry. His professional career includes significant roles in both academia and industry, including a position as a Senior Principal Scientist at Boehringer Ingelheim Pharmaceuticals from 1988 to 2008 and as a Visiting Assistant Professor of Biochemistry at Quinnipiac University for a brief period in 2009 to 2010.
Achievements in Drug Discovery
During his tenure at Boehringer Ingelheim Pharmaceuticals, Richard Ingraham was a member of the pre-clinical team that advanced Viramune, recognized as the first successful non-nucleoside reverse transcriptase inhibitor. He has developed novel screening assays and characterized proteins, ligands, and interactions to elucidate structure-activity relationships (SAR), contributing to advancements in drug discovery.
Skills in Biochemistry and Drug Development
Richard Ingraham possesses a robust skill set in protein purification, protein modification and chemistry, and peptide chemistry, including synthesis, purification, and modification. His specialization extends to project involvement in target identification and validation, pathway analysis, and bioinformatics across various therapeutic areas, including cardiovascular, metabolic, inflammatory, immunological, pulmonary, CNS, and virology. His strong background in eicosanoids further enhances his expertise in biochemistry and drug discovery.